In:
Cancer Science, Wiley, Vol. 106, No. 10 ( 2015-10), p. 1341-1350
Abstract:
Magnolol, the major active compound found in Magnolia officinalis has a wide range of clinical applications due to its anti‐inflammation and anti‐oxidation effects. This study investigated the effects of magnolol on the growth of human gallbladder carcinoma ( GBC ) cell lines. The results indicated that magnolol could significantly inhibit the growth of GBC cell lines in a dose‐ and time‐dependent manner. Magnolol also blocked cell cycle progression at G 0 /G 1 phase and induced mitochondrial‐related apoptosis by upregulating p53 and p21 protein levels and by downregulating cyclin D1, CDC 25A, and Cdk2 protein levels. When cells were pretreated with a p53 inhibitor (pifithrin‐a), followed by magnolol treatment, pifithrin‐a blocked magnolol‐induced apoptosis and G 0 /G 1 arrest. In vivo , magnolol suppressed tumor growth and activated the same mechanisms as were activated in vitro . In conclusion, our study is the first to report that magnolol has an inhibitory effect on the growth of GBC cells and that this compound may have potential as a novel therapeutic agent for the treatment of GBC .
Type of Medium:
Online Resource
ISSN:
1347-9032
,
1349-7006
DOI:
10.1111/cas.2015.106.issue-10
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
2115647-5
detail.hit.zdb_id:
2111204-6
Permalink